Researchers at the University of California, San Diego School of Medicine have erased and reactivated memories in rats, profoundly altering the animals’ reaction to past events.
The study, published in the June 1 advanced online issue of the journal Nature, is the first to show the ability to selectively remove a memory and predictably reactivate it by stimulating nerves in the brain at frequencies that are known to weaken and strengthen the connections between nerve cells, called synapses.
Segment on Alzheimer's disease begins at 3:10.
Last week, many news stories broke about a recent study suggesting levels of amyloid, the sticky substance that builds up in the brain of Alzheimer's patients, may be lowered by the antidepressant Celexa. Dr. Rudy Tanzi, of Harvard Medical School/Massachusetts General Hospital and chair of Cure Alzheimer's Fund's Research Consortium, appeared on the CBS Morning Show to discuss the story.
Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).
A new blood test, which has the potential to accurately diagnose Alzheimer’s disease in individuals and significantly advance drug testing and research on the disease, has been developed through grant funding by Cure Alzheimer's Fund.
The test, known as Immunosignature (IS) and developed by a team led by UCLA neurologist Lucas Restrepo, uses a special method of fluorescent tagging of antibodies in the blood to recognize an identifiable binding pattern—or antibody "signature"—associated with Alzheimer's.
At its core, Alzheimer’s is a disease that disrupts communications between neurons (nerve cells) in the brain, and ultimately kills those neurons. Cure Alzheimer’s Fund has committed to understanding this destructive process as a necessary component to stopping the disease. To that end, it has recruited four of the world’s top experts in the field: University of California, San Diego’s Roberto Malinow, Stanford’s Robert Malenka and Thomas Südhof, and Rick Huganir at Johns Hopkins.
We collected your questions about Alzheimer's from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below!
Greg O’Brien is a reporter from Brewster, Mass. He is the former editor and publisher of the Cape Codder and an award-winning writer. O’Brien was diagnosed with early-onset Alzheimer's disease in 2010. The following is an excerpt from a speech he gave on March 13, 2014.
Over the past few years, our understanding of Alzheimer’s disease has increased immensely. We can now identify three distinct parts of the disease pathology: early-stage Abeta (amyloid) accumulation, mid-stage development of tau tangles, and late-stage inflammation.
Scientists on our Research Consortium are investigating all three of these points of intervention. On March 6, we talked to Drs. Steven Wagner, David Holtzman, and Rudy Tanzi about how their labs are working to stop Alzheimer’s in its early, middle, and late stages.
Bruce Yankner, M.D., Ph.D., led a recent study (not funded by Cure Alzheimer's Fund) on a protein called REST. His results suggest that this protein may protect neurons from damage such as oxidative stress and inflammation. The study also gives us clues as to why plaques and tangles, two well-known features of Alzheimer's pathology, may not always cause cognitive decline.
© 2005-2016 Cure Alzheimer's Fund. All rights reserved.